BOARD OF DIRECTORS

Suzanne L. Bruhn, Ph.D.

Suzanne Bruhn, Ph.D., has been a member of the board of directors of Travere Therapeutics, Inc. since 2020. She brings to the Travere board more than 20 years of biopharmaceutical experience and a proven track record of success in the development and commercialization of therapies for the treatment of serious diseases with significant unmet needs. Dr. Bruhn serves as the president and chief executive officer of biotechnology company Tiaki Therapeutics Inc., where she is responsible for the vision and overall corporate and capital strategy of the company as it develops innovative therapeutics for patients with neurodegenerative diseases. Prior to her role at Tiaki, Dr. Bruhn served as the president and chief executive officer of Proclara Biosciences where she led the company’s strategy to develop novel treatments for neurodegenerative and peripheral protein misfolding diseases. Before joining Proclara, Dr. Bruhn served as president and chief executive officer of Promedior, Inc., where she focused the company’s strategy on clinical stage development for rare diseases. Earlier in her career, Dr. Bruhn spent 13 years at Shire Human Genetic Therapies, where she held a series of positions of increasing responsibility, including leading global regulatory affairs, strategic planning and program management. Dr. Bruhn currently serves as an independent director on the boards of clinical stage biotechnology companies Cerecor, Inc., Vigil Neuroscience, Mind Medicine Inc. (also known as MindMed), and Pliant Therapeutics. She holds a bachelor’s degree in chemistry from Iowa State University, a Ph.D. in chemistry from the Massachusetts Institute of Technology, and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School.